Related Experiment Video
Updated: Jul 29, 2026
Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
Differential kinetics of drug resistance in human leukaemic cells measured by SCGE/CLSM
L M Ball1, C L Lannon, G R Langley
1Department of Clinical Haemato-Oncology, Dalhousie University, JWK Grace Health Centre, Halifax, Nova Scotia, Canada.
Background:
New analogues of DNA directed chemotherapy moieties are available for comparative efficacy testing in human neoplastic disease. In addition to MTT testing direct assessment of DNA excision repair activity after direct exposure of marrow cells may provide information on relative DNA effects in vitro.
Aims:
To assess the ability of SCGE/high resolution CLSM to detect differences in drug resistance between human neoplastic cell lines in the DNA excision repair response to chemotherapy.
Methods:
Eight human leukaemia samples (4 childhood, 4 adult) were exposed to 1 hour of single concentrations of daunorubicin, DaunoXome (courtesy NeXstar Pharmaceuticals Inc, USA), cyclophosphamide and 4-hydroperoxycyclophosphamide (4-HC, courtesy Dr. M. Colvin, Duke University, USA), followed by SCGE/high resolution CLSM with quantitation of total excised DNA. Differences between cases/drug moieties/exposures were analysed.
Results:
Although generally equal effect dose levels for DaunoXome were lower than for standard daunorubicin, patients/individual neoplastic cells differed considerably in optimal dose levels. Conventional cyclophosphamide in comparison to 4-HC showed inconsistent results indicating considerable differences in the level of drug resistance to the conventional product.
Conclusions:
Direct testing for drug resistance patterns in DNA directed drug moieties by SCGE/CLSM reveals individual variability of human malignant cell lines warranting comparison with results of MTT testing and in-vivo patient response.
Insights
This study shows that DNA excision repair activity testing using SCGE/CLSM can reveal individual drug resistance variations in human leukemia cells, aiding personalized chemotherapy. This method offers insights beyond standard MTT assays for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Novel DNA-directed chemotherapy agents require efficacy testing in human cancers.
- Assessing DNA excision repair activity in marrow cells offers an in vitro method to evaluate drug effects.
Purpose of the Study:
- To evaluate the efficacy of the comet assay (SCGE) coupled with confocal laser scanning microscopy (CLSM) in detecting differential drug resistance.
- To assess DNA excision repair responses to chemotherapy in human neoplastic cell lines.
Main Methods:
- Eight human leukemia samples (pediatric and adult) were exposed to daunorubicin, DaunoXome, cyclophosphamide, and 4-hydroperoxycyclophosphamide (4-HC).
- DNA excision repair activity was measured using SCGE/high resolution CLSM, quantifying total excised DNA.
- Data analysis focused on differences between patient samples, drug types, and exposure levels.
Main Results:
- DaunoXome generally required lower doses than standard daunorubicin for equivalent effects, but optimal doses varied significantly between patients.
- Conventional cyclophosphamide yielded inconsistent results compared to 4-HC, indicating substantial differences in drug resistance.
- Significant inter-individual variability in drug resistance was observed at the cellular level.
Conclusions:
- Direct assessment of drug resistance patterns using SCGE/CLSM for DNA-directed agents highlights individual variability in human cancer cell lines.
- This method provides valuable data for comparison with MTT assays and in vivo patient responses.
- SCGE/CLSM offers a promising approach for personalized cancer therapy by revealing specific drug resistance profiles.
